Barrett’s esophagus: Review of natural history and comparative efficacy of endoscopic and surgical therapies

doi:10.4251/wjgo.v14.i3.568

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 3

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5419)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-8) series.

Item

Count

PDF

251

WORD

HTML

2758

Figures (1-1)

280

Tables (1-8)

335

Sum=3696

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

299

Download

497

Sum=796

Publishing Process of This Article

Item

Count

Browse

342

Download

585

Sum=927

Mar 15, 2022 (publication date) through Nov 5, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Oncol. Mar 15, 2022; 14(3): 568-586
Published online Mar 15, 2022. doi: 10.4251/wjgo.v14.i3.568

Table 6 Efficacy of endoscopic eradication therapy for Barrett’s esophagus with submucosal adenocarcinoma

Ref.	Type	n	Eradication of cancer	Survival
Manner et al[81]	Retrospective	61	87% (including HGD)	5-yr OS 84%
Ngamruengphong et al[120]	Retrospective	39	-	5-yr OS 66%
Schölvinck et al[78]	Retrospective	43	-	Median survival: 46 mo
Künzli et al[122]	Retrospective (RFA or APC)	35	100%	-
Semenkovich et al[74]	Retrospective	588	-	5-yr OS 50%
Otaki et al[77]	Retrospective (RFA/APC/Cryo)	73	63% (including HGD)	5-yr OS 59%

APC: Argon plasma coagulation; Cryo: Cryotherapy; HGD: High grade dysplasia; OS: Overall survival; RFA: Radiofrequency ablation.

Citation: Choi KKH, Sanagapalli S. Barrett’s esophagus: Review of natural history and comparative efficacy of endoscopic and surgical therapies. World J Gastrointest Oncol 2022; 14(3): 568-586
URL: https://www.wjgnet.com/1948-5204/full/v14/i3/568.htm
DOI: https://dx.doi.org/10.4251/wjgo.v14.i3.568